Professor of Integrative Medical Sciences
Dr. Yanqiao Zhang is a full Professor in the Department of Integrative Medical Sciences. He received his MD degree and MS degree from Wuhan University School of Medicine. Dr. Zhang did his postdoctoral trainings in West Virginia University and University of California at Los Angeles. He joined NEOMED as Assistant Professor in 2008. Dr. Zhang has received numerous awards and honors, such as Postdoctoral Fellowship award, Scientist Development award, and Beginning Grant-in-Award from American Heart Association (AHA), George J. Popjak Scholar Award on Atherosclerosis (UCLA), Junior Faculty Award (NEOMED), Fellow of AHA, and Outstanding Research Award (NEOMED). He has published papers in PNAS, Genes and Development, Nature Communications, Hepatology, etc. Dr. Zhang’s research is currently supported by NIH R01s.
Area of Expertise/Research Interests
Dr. Zhang’s research focuses on understanding the pathogenesis of diseases associated with dysregulation of lipid, bile acid and/or glucose metabolism, such as fatty liver diseases, diabetes, obesity and atherosclerosis, in hoping for identifying novel therapeutic targets or approaches for treatment of these common metabolic disorders.
- Molecules to Cells (Biological Chemistry)
- Cell Signaling
- Molecular Cloning and Genetic Engineering
Academic & Professional Activities
- Standing member, NIH Hepatobiliary Pathophysiology (HBPP) Study Section (2015-2019)
- Editorial Board, Hepatology (2016 – 2019)
- Academic Editor, Scientific Report (2015 – )
- Program Committee, AHA Scientific Sessions Meeting (2013 – 2015)
- AHA Innovative Award study section (2019 – )
- AHA Postdoctoral Fellowship Award
- AHA Scientist Development Award
- AHA Beginning Grant-in-Aid award
- George J. Popjak Scholar Award on Atherosclerosis (UCLA)
- Outstanding Research Award (NEOMED)
- Editorial Board, Hepatology, 2016 – 2019
- Academic Editor, Scientific Reports, 2015 –
- Academic Editor, PLoS One, 2013 – 2018
- Standing member, NIH HBPP Study Section, 2015-2019
- Standing member, AHA Lipid and Lipoprotein Study Section, 2010-2014
- Wayne State University, Detroit, MI. November, 2019
- University of Pittsburgh, Pittsburgh, PA. January 2019 and November 2018
- 2018 International Meeting on 22nd MDO and 33rd JSSX. Kanazawa, Japan. October 2018.
- Loyola University, Chicago, IL. November 2017
- Southeast Lipid Research Conference, Lexington, Kentucky. November 2017
- Xu Y, Xu Y, Zhu Y, Sun H, Juguilon C, Li F, Fan D, Yin L, Zhang Y. Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis. Mol Ther. 2020 Jan 8;28(1):202-216. PubMed PMID: 31604677. PMCID: PMC6952168.
- Li Y, Xu Y, Jadhav K, Zhu Y, Yin L, Zhang Y. Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1574-1587. PMID: 31291759. PMCID: PMC6656627.
- Jadhav K, Xu Y, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, Zhang Y. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab. 2018 Mar;9:131-140. PMID: 29361497. PMCID: PMC5870099.
- Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, ER stress and lipogenesis and is regulated by HNF4alpha. 2016. Hepatology. 63(6):1860-74. PMID: 26806650. PMCID: PMC4874867
- Xu, Y., Zalzala, M., Xu, J., Li, Y., Yin, L., and Zhang, Y. 2015. A Metabolic Stress-inducible miR-34a-HNF4a Pathway Regulates Lipid and Lipoprotein Metabolism. Nature Communications, 6:7466. doi: 10.1038/ncomms8466. PMID: 26100857. PMCID: PMC4479415